M
Maria Domenica Cappellini
Researcher at University of Milan
Publications - 570
Citations - 21441
Maria Domenica Cappellini is an academic researcher from University of Milan. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 71, co-authored 518 publications receiving 18668 citations. Previous affiliations of Maria Domenica Cappellini include Centra & Vita-Salute San Raffaele University.
Papers
More filters
Journal ArticleDOI
Gaucher disease for the haematologist: An expert interview with Maria Domenica Cappellini
TL;DR: In this article, the authors proposed a method to solve the problem of the problem: the one-dimensional graph.
↵.↵↵]↵
Journal ArticleDOI
Hematologic and Hemato-Oncologic Aspects of Gaucher Disease
Derralynn Hughes,Maria Domenica Cappellini,Marc G. Berger,Jan Van Droogenbroeck,Maaike de Fost,Dragana Janic,Theodore Marinakis,Hanna Rosenbaum,Jesús Villarubia,Elena Zhukovskaya,Carla E. M. Hollak +10 more
TL;DR: S88 Volume 29 Supplement C Hematologic and Hemato-Oncologic Aspects of Gaucher Disease Derralynn Hughes, MA, DPhil, MRCP, MARCPath, MECPath, and Carla Hollak are summarized.
Journal ArticleDOI
Metastatic Spreading of Community Acquired Staphylococcus aureus Bacteraemia.
TL;DR: Raised awareness of S. aureus bacteraemia in patients without healthcare-associated risk factors is important in the diagnosis, management, and control of this infection, because failure to recognise patients with serious infection and lack of understanding of empirical antimicrobial selection are associated with a high mortality rate in otherwise healthy people.
Coagulopathy in Beta-Thalassemia: Current Understanding and
M. Domenica Cappellini,Khaled M. Musallam,Maria Domenica Cappellini,Regina Elena Irccs,Alessia Marcon,Ali T. Taher +5 more
TL;DR: In this review, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, and the current clinical experience is summarized.
Journal ArticleDOI
Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
Khaled M. Musallam,Ali T. Taher,Antonis Kattamis,Kevin H.M. Kuo,Sujit Sheth,Maria Domenica Cappellini +5 more
TL;DR: Luspatercept as discussed by the authors is an erythroid maturation agent that has been evaluated in a Phase 2, randomized trial and showed a significant benefit in raising hemoglobin level by at least 1 g/dL in adults with β-thalassemia and a baseline haemoglobin level ≤ 10 g/dl.